The FINEARTS-HF trial found that treatment with finerenone reduced the risk of macroalbuminuria in patients with heart failure, but did not significantly impact estimated glomerular filtration rate (eGFR)-based kidney outcomes. The study showed that finerenone improved heart failure outcomes and cardiovascular mortality, with no significant kidney benefits observed. Patients on finerenone had no significant differences in kidney outcomes compared to those on placebo. Despite the lack of significant changes, finerenone did reduce the risk of new onset macroalbuminuria in patients with baseline albuminuria levels below 300 mg/g. Overall, the study highlights the potential benefits of finerenone in patients with heart failure, despite limited impact on kidney outcomes.
Source link
Limited Kidney Benefits With Finerenone in Heart Failure
